A leading biopharma R&D company that provides access to the best science and has world class in-house technology platforms. We operate with a top-notch pharma development approach ensured by our people, technology, laboratory infrastucture and international network.
We are experts in optimizing natural peptides/proteins for therapeutical purposes and to be
used in cell and gene therapy (CGT). Miniproteins possess highly useful attributes (e.g.
stability, solubility, low immunogenicity) and these features are maintained during the
directed evolution. In contrast, other attributes, such as affinity towards the
pharmacological target/ligand or off-target proteins are altered profoundly during the
process.
WE APPLY THIS APPROACH IN TWO PLATFORMS:
ISEPTM (Individual Sequence Enrichment Pattern) PLATFORM TO CREATE
MINIPROTEIN-BASED
BIOPHARMACEUTICALS AND CELL AND GENE THERAPY PRODUCTS. We
create peptide megalibraries with more than a million candidates from which promising leads
can
be selected and developed for specific targets leveraging big data analytics. We combine
state-of-the-art in silico and wet lab tools in our proprietary ISEP platform to identify
high
quality drug candidates with unprecedented speed. These peptides can be utilized in cell
therapies such as CAR-T therapy or GMO enterobacteria.
CREATeTM (Chemogenetic Receptor Engineering for Advanced Therapeutics) PLATFORM
FOR SMALL MOLECULE CONTROLLED GENE THERAPY. We are creating
engineered receptor – actuator pairs, where the receptor has lost its ability to bind its
endogenous ligand, has no constitutive activity, but is activated by extremely low
concentration
of its actuator. To reach this goal, a megalibrary of cell-surface receptors or ion channels
is
generated and the members are screened for the advantageous characteristics. This technique
may
create a novel therapeutic class that can be utilized for the treatment of various
debilitating
CNS diseases.
We also run a drug repositioning (fixed-dose combinations, FDC) project in one of our
partner
laboratories to create new, safe and effective therapeutic options using drugs already on
the
market.
Our projects are managed applying a state of the art project management approach for discovery and pre-clinical development. We rely on the broad experience of our scientists in a wide range of in vitro and in vivo methodologies..
We are constantly looking for world class talent, join us if you want to work in an agile environment to stay ahead of the game in healthcare.